Paul Tudor Jones’s Gyre Therapeutics GYRE Stock Holding History

Paul Tudor Jones’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,932	Closed	-$67K	–	1157
2017 Q2	$67K	Buy	+1,932	New	+$69.4K	﹤0.01%	974

Other funds holding GYRE

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

FPF

FNY Partners Fund New York $185M AUM 32.59% 1-Year Est. Return

Paul Tudor Jones's GYRE Position: Q3 2017 in Review

Paul Tudor Jones sold out of Gyre Therapeutics (GYRE) in Q3 2017, closing a stake of 1,932 shares — an estimated $67K sold.

Paul Tudor Jones first reported a position in GYRE in Q2 2017 and held it in 1 quarter. The position peaked at $67K in Q2 2017. 19 funds tracked by Wall St. Rank hold GYRE as of Q3 2017.

Paul Tudor Jones reported no remaining Gyre Therapeutics position as of Q3 2017 after selling out during the quarter.
Paul Tudor Jones sold 1,932 Gyre Therapeutics shares in Q3 2017, an estimated $67K.
Paul Tudor Jones first reported a position in Gyre Therapeutics in Q2 2017 and held it in 1 quarter.
Paul Tudor Jones's Gyre Therapeutics position peaked at $67K in Q2 2017.
19 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2017.

Based on Tudor Investment Corp's 13F filing for Q3 2017, filed 14 Nov 2017.